Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,706 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all

Conditions: Human Immunodeficiency Virus I Infection
Interventions: Mycophenolate Mofetil 500Mg Tab; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Enrollment: 23 participants
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, HIV Seronegativity
Interventions: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1; Biological
Lead sponsor: VaxGen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: HIV Infections
Interventions: Amprenavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 4 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: PTSD, Depression, Virus, Human Immunodeficiency
Interventions: WAVE-TW; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV/AIDS, Insomnia
Interventions: SHUTi; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hepatitis C, Medication Adherence
Interventions: Intensive Models (mDOT and CGT) of HCV Care; Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Sexually Transmitted Infection
Interventions: brief motivation intervention; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 54 Years
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Raltegravir poloxamer film coated tablet, Raltegravir chewable tablet, Raltegravir oral granules for suspension (20 mg/mL); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 29
States / cities: Alhambra, California • La Jolla, California • Los Angeles, California + 19 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more

Conditions: HIV Infections
Interventions: HST-NEETs; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infection
Interventions: emtricitabine/tenofovir, abacavir/lamivudine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more

Conditions: Cardiovascular Diseases, Hepatitis C, Hiv
Interventions: Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI; Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: HIV-1-infection
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC); Drug
Lead sponsor: The Crofoot Research Center, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: PML, AIDS
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more

Conditions: HIV Infections
Interventions: Atazanavir, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 4
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Methadone, Buprenorphine and Norbuprenorphine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Overland Park, Kansas

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Clarithromycin, Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 13 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 44
States / cities: Phoenix, Arizona • Harbor City, California • Irvine, California + 34 more

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: ABBV-382, Placebo for ABBV-382; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: HIV-1 Peptide Immunogen, Multivalent; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alcohol Drinking, Chronic Inflammation, Neurocognitive Dysfunction, Liver Diseases, HIV Infections
Interventions: Contingency Management (CM); Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 50 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections, Cytopenias
Interventions: Zidovudine, Sargramostim; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, HIV Infections
Interventions: telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose); Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 11
States / cities: Beverly Hills, California • San Diego, California • San Francisco, California + 8 more

Search by objective public record fields.

MMF for HIV Reservoir Reduction

Growth Hormone Dynamics and Cardiac Steatosis in HIV

Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection

A Study of Amprenavir in HIV-Infected Patients

Writing to Alleviate Violence Exposure for Transgender Women (WAVE-TW)

Cognitive Behavioral Therapy to Treat Insomnia in Persons With HIV Infection

Intensive Models of HCV Care for Injection Drug Users

Brief Intervention to Reduce STDs in ER Drug Users

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

30-to-90 Day Challenge: Effects of Alcohol Cessation on Health Outcomes

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV